Hem › Bröstcancer › Tennessee › Nashville
Kliniska studier för Bröstcancer i Nashville, TN
81 studier för Bröstcancer söker deltagare vid platser i och runt Nashville (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
RekryterarFas 3
- Tennessee Oncology, PLLC, Nashville
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
RekryterarFas 1
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Nashville
A Study of PHST001 in Advanced Solid Tumors
RekryterarFas 1
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekryterarFas 1/2
- Sarah Cannon Research Institute, Nashville
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
RekryterarFas 2
- SCRI Oncology Partners, Nashville
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
RekryterarFas 3
- Sarah Cannon Research Institute, Nashville
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
RekryterarFas 2
- Sarah Cannon Research Institute (Nashville), Nashville
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RekryterarFas 2
- SCRI Oncology Partners, Nashville
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
RekryterarFas 1/2
- SCRI Oncology Partners, Nashville
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
RekryterarFas 2
- Tennessee Oncology, Greco-Hainsworth Center for Research, Nashville
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
RekryterarFas 1
- SCRI Oncology Partners, Nashville
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RekryterarFas 1/2
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Pllc, Nashville
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
RekryterarFas 1
- Research Site, Nashville
IKS014 in Advanced Solid Tumors That Express HER2
RekryterarFas 1
- Tennessee Oncology, Nashville
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
RekryterarFas 1
- Scri Oncology Partners, Nashville
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
RekryterarFas 3
- SCRI Oncology Partners ( Site 7000), Nashville
- Tennessee Oncology ( Site 0068), Nashville
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
RekryterarFas 3
- Research Site, Nashville
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
RekryterarFas 3
- SCRI Oncology Partners ( Site 7005), Nashville
- Nashville General Hospital ( Site 0017), Nashville
- Vanderbilt-Ingram Cancer Center ( Site 0038), Nashville
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
RekryterarFas 1/2
- Vanderbilt Ingram Cancer Center, Nashville
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Rekryterar
- Vanderbilt, Nashville
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
RekryterarFas 3
- Clinical Trial Site, Nashville
- Clinical Trial Site, Mount Juliet · 15 mi bort
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
RekryterarFas 3
- Sarah Cannon Research Institute SCRI, Nashville
- Nashville General Hospital, Nashville
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
RekryterarFas 2
- Tennessee Oncology, Nashville
A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
RekryterarFas 1
- SCRI Oncology Partners, Nashville
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
RekryterarFas 1/2
- SCRI Oncology Partners, Nashville
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
RekryterarFas 3
- Tennessee Oncology, Nashville
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
RekryterarFas 1/2
- Sarah Cannon Nashville, Nashville
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
RekryterarFas 3
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, PLLC, Nashville
- Henry - Joyce Cancer Clinic, Nashville
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
RekryterarFas 1/2
- Tennessee Oncology PLLC, Nashville
- Vanderbilt University Medical Center, Nashville
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
RekryterarFas 2
- SCRI Oncology Partners ( Site 7000), Nashville
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RekryterarFas 1
- Sarah Cannon Research Institute, Nashville
A Phase 1/1b Study of IAM1363 in HER2 Cancers
RekryterarFas 1
- SCRI Oncology Partners, Nashville
- Vanderbilt Ingram Cancer Center, Nashville
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
RekryterarFas 1
- Sarah Cannon Research Center, Nashville
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
RekryterarFas 1/2
- SCRI Oncology Partners, Nashville
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
RekryterarFas 3
- Research Site, Nashville
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
RekryterarFas 1/2
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
RekryterarFas 1/2
- Sarah Cannon Research Institute Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Institute, Nashville
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RekryterarFas 3
- Vanderbilt University Medical Center, Nashville
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
RekryterarObservationsstudie
- Nashville General, Nashville
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
RekryterarFas 1/2
- Tennessee Oncology, Nashville
A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer
RekryterarFas 1
- Sarah Cannon Research Institute/SCRI, Nashville
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
RekryterarFas 1/2
- SCRI Oncology Partners, Nashville
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
RekryterarFas 2
- Vanderbilt Cancer Center, Nashville
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
RekryterarFas 1
- SCRI Oncology Partners - Nashville, Nashville
Collecting and Storing Tissue Samples From Women With or Without Breast Cancer
RekryterarObservationsstudieFriska volontärer välkomna
- Vanderbilt-Ingram Cancer Center, Nashville
ATEMPT 2.0: Adjuvant T-DM1 vs TH
RekryterarFas 2
- Greco-Hainsworth Centers for Research/Tennessee Oncology, Nashville
- SCRI Oncology Partners, Nashville
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
RekryterarFas 3
- SCRI Oncology Partners, Nashville
E-Mindfulness Approaches for Living After Breast Cancer
RekryterarFas 3
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RekryterarFas 1/2
- Sarah Cannon Research Institute at Tennessee Oncology, Nashville
- Tennessee Oncology, Nashville
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
RekryterarFas 1/2
- Tennessee Oncology PLLC, Nashville
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
RekryterarFas 2
- SCRI - TriStar Medical Group Children's Specialists, Nashville
- SCRI Oncology Partners, Nashville
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RekryterarFas 1
- Investigative Site #102, Nashville
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
RekryterarFas 2
- SCRI Oncology Partners, Nashville
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
RekryterarFas 1/2
- Sarah Cannon Research Institute, Nashville
Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
RekryterarFas 1/2
- SCRI Oncology Partners, Nashville
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
RekryterarFas 1/2
- Sarah Cannon Research Institute (SCRI), Nashville
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
RekryterarFas 1/2
- Sarah Cannon Research Institute, Nashville
Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy
RekryterarTidig fas 1
- Vanderbilt University Medical Center, Nashville
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
RekryterarFas 1/2
- Sarah Cannon Research Institute, Nashville
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RekryterarFas 3
- SCRI Oncology Partners, Nashville
- Henry-Joyce Cancer Clinic, Nashville
Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
Rekryterar
- Vanderbilt-Ingram Cancer Center, Nashville
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RekryterarFas 2
- Vanderbilt University, Nashville
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
RekryterarFas 2
- Vanderbilt-Ingram Cancer Center, Nashville
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
RekryterarFas 3
- The Children's Hospital at TriStar Centennial, Nashville
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
RekryterarFas 1
- Sarah Cannon Cancer Center, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
RekryterarFas 1/2
- Vanderbilt University Medical Center, Nashville
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
RekryterarFas 2
- Vanderbilt University, Nashville
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
RekryterarFas 1/2
- Tennessee Oncology, PLLC, Nashville
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
RekryterarFas 2
- SCRI Oncology Partners, Nashville
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
RekryterarFas 1
- Sarah Cannon Research Institute, Nashville
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
RekryterarFas 1
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
- Vanderbilt University Medical Center, Nashville
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
RekryterarFas 2
- Vanderbilt University/Ingram Cancer Center, Nashville
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
RekryterarObservationsstudieFriska volontärer välkomna
- Vanderbilt-Ingram Cancer Center, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekryterarObservationsstudie
- Massive Bio SYNERGY-AI site, Nashville
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
RekryterarFas 1/2
- Tennessee Oncology, Nashville
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
RekryterarFas 1
- Tennessee Oncology, Nashville
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
RekryterarFas 1
- Exelixis Clinical Site #6, Nashville
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
RekryterarObservationsstudie
- Nashville Breast Center, Nashville
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
RekryterarFas 2
- SCRI Oncology Partners, Nashville
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
RekryterarFas 1/2
- SCRI Oncology Partners, Nashville
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
RekryterarFas 1
- SCRI Oncology Partners, Nashville
Bröstcancer-studier i andra städer
- New York City, NY136 studier
- Houston, TX126 studier
- Boston, MA112 studier
- Los Angeles, CA73 studier
- Edison, NJ68 studier
- St. Louis, MO64 studier
- Queens, NY64 studier
- Durham, NC64 studier
- Chicago, IL59 studier
- Philadelphia, PA56 studier
- Dallas, TX55 studier
- Arlington, VA47 studier
Andra studier i Nashville
- Icke-småcellig lungcancer97 studier
- Metastaserande cancer70 studier
- Kolorektal cancer69 studier
- Cancer (alla typer)65 studier
- Äggstockscancer49 studier
- Prostatacancer43 studier
- Lungcancer40 studier
- Plattenepitelcancer i huvud och hals39 studier
- Bukspottkörtelcancer39 studier
- Endometriecancer38 studier
- Melanom33 studier
- Multipelt myelom32 studier
Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.